Xilio Therapeutics analyst ratings
Xilio Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2022 | 745.13% | Morgan Stanley | $32 → $20 | Maintains | Overweight |
| 01/10/2022 | 1421.23% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
| 11/16/2021 | 1209.95% | Raymond James | → $31 | Initiates Coverage On | → Outperform |
| 11/16/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/16/2021 | 1252.21% | Morgan Stanley | → $32 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/10/2022 | 745.13% | 摩根士丹利 | 32 美元 → 20 美元 | 維護 | 超重 |
| 2022 年 10 月 1 日 | 1421.23% | HC Wainwright & Co. | → 36 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/16/2021 | 1209.95% | 雷蒙德·詹姆 | → 31 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 11/16/2021 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 11/16/2021 | 1252.21% | 摩根士丹利 | → 32 美元 | 啓動覆蓋範圍開啓 | → 超重 |
Xilio Therapeutics Questions & Answers
Xilio Therapeutics 問題與解答
The latest price target for Xilio Therapeutics (NASDAQ: XLO) was reported by Morgan Stanley on August 10, 2022. The analyst firm set a price target for $20.00 expecting XLO to rise to within 12 months (a possible 745.13% upside). 5 analyst firms have reported ratings in the last year.
摩根士丹利於2022年8月10日公佈了Xilio Therapeutics（納斯達克股票代碼：XLO）的最新目標股價。該分析公司將目標股價設定爲20.00美元，預計XLO將在12個月內上漲至20.00美元（可能上漲745.13％）。去年有5家分析公司公佈了評級。
The latest analyst rating for Xilio Therapeutics (NASDAQ: XLO) was provided by Morgan Stanley, and Xilio Therapeutics maintained their overweight rating.
Xilio Therapeutics（納斯達克股票代碼：XLO）的最新分析師評級由摩根士丹利提供，Xilio Therapeutics維持其增持評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xilio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xilio Therapeutics was filed on August 10, 2022 so you should expect the next rating to be made available sometime around August 10, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Xilio Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Xilio Therapeutics的最後一次評級是在2022年8月10日發佈的，因此您應該預計下一個評級將在2023年8月10日左右公佈。
While ratings are subjective and will change, the latest Xilio Therapeutics (XLO) rating was a maintained with a price target of $32.00 to $20.00. The current price Xilio Therapeutics (XLO) is trading at is $2.37, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Xilio Therapeutics（XLO）評級維持不變，目標股價爲32.00美元至20.00美元。Xilio Therapeutics（XLO）目前的交易價格爲2.37美元，超出了分析師的預期區間。